OSR홀딩스(OSRH)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.32 (+11.66%), 시가총액 $0.02B, 52주 범위 $0.40 ~ $1.67.
OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Germany, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis. In addition, the comp
OSR홀딩스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
OSR홀딩스의 현재 주가는 $0.32 (+11.66%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
OSR홀딩스의 시가총액은 약 $0.02B입니다.
OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Germany, Switzerland, and South Korea. The company develops immunothe